These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
26. Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma. Kyle RA; Rajkumar SV Hematol Oncol Clin North Am; 2007 Dec; 21(6):1093-113, ix. PubMed ID: 17996590 [TBL] [Abstract][Full Text] [Related]
27. Long-term follow-up of patients with monoclonal gammopathy of undetermined significance after kidney transplantation. Naina HV; Harris S; Dispenzieri A; Cosio FG; Habermann TM; Stegall MD; Dean PG; Prieto M; Kyle RA; Rajkumar SV; Leung N Am J Nephrol; 2012; 35(4):365-71. PubMed ID: 22473253 [TBL] [Abstract][Full Text] [Related]
28. A contribution to examination of propidium iodide and annexin V plasma cells indices in multiple myeloma. Scudla V; Ordeltova M; Bacovsky J; Vytrasova M; Sumna E; Martinek A; Horak P Neoplasma; 2003; 50(5):363-71. PubMed ID: 14628090 [TBL] [Abstract][Full Text] [Related]
29. Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma. Lokhorst HM; Plesner T; Laubach JP; Nahi H; Gimsing P; Hansson M; Minnema MC; Lassen U; Krejcik J; Palumbo A; van de Donk NW; Ahmadi T; Khan I; Uhlar CM; Wang J; Sasser AK; Losic N; Lisby S; Basse L; Brun N; Richardson PG N Engl J Med; 2015 Sep; 373(13):1207-19. PubMed ID: 26308596 [TBL] [Abstract][Full Text] [Related]
30. Therapeutic Advances in the Management of Smoldering Myeloma. Khan R; Zahid U; Kollu V; Jahan N; Ali M; Tricot G; Anwer F Am J Ther; 2020; 27(2):e194-e203. PubMed ID: 31842112 [TBL] [Abstract][Full Text] [Related]
31. Pathway-based network analysis of myeloma tumors: monoclonal gammopathy of unknown significance, smoldering multiple myeloma, and multiple myeloma. Dong L; Chen CY; Ning B; Xu DL; Gao JH; Wang LL; Yan SY; Cheng S Genet Mol Res; 2015 Aug; 14(3):9571-84. PubMed ID: 26345890 [TBL] [Abstract][Full Text] [Related]
32. A phase I study of PankoMab-GEX, a humanised glyco-optimised monoclonal antibody to a novel tumour-specific MUC1 glycopeptide epitope in patients with advanced carcinomas. Fiedler W; DeDosso S; Cresta S; Weidmann J; Tessari A; Salzberg M; Dietrich B; Baumeister H; Goletz S; Gianni L; Sessa C Eur J Cancer; 2016 Aug; 63():55-63. PubMed ID: 27285281 [TBL] [Abstract][Full Text] [Related]
33. Bone marrow angiogenesis in 400 patients with monoclonal gammopathy of undetermined significance, multiple myeloma, and primary amyloidosis. Rajkumar SV; Mesa RA; Fonseca R; Schroeder G; Plevak MF; Dispenzieri A; Lacy MQ; Lust JA; Witzig TE; Gertz MA; Kyle RA; Russell SJ; Greipp PR Clin Cancer Res; 2002 Jul; 8(7):2210-6. PubMed ID: 12114422 [TBL] [Abstract][Full Text] [Related]
36. An open-label, phase 2 trial of denosumab in the treatment of relapsed or plateau-phase multiple myeloma. Vij R; Horvath N; Spencer A; Taylor K; Vadhan-Raj S; Vescio R; Smith J; Qian Y; Yeh H; Jun S Am J Hematol; 2009 Oct; 84(10):650-6. PubMed ID: 19714603 [TBL] [Abstract][Full Text] [Related]
37. [Analysis of serum levels of Dickkopf-1 (DKK-1) in monoclonal gammopathy of undetermined significance and multiple myeloma]. Ščudla V; Petrová P; Pika T; Lochman P; Minařík J; Bačovský J; Srovnalík K Cas Lek Cesk; 2015; 154(4):181-8. PubMed ID: 26357861 [TBL] [Abstract][Full Text] [Related]
38. Comment on: Monoclonal gammopathy of undetermined significance, smoldering multiple myeloma, and curcumin: a randomized, double-blind placebo-controlled crossover 4g study and an open-label 8g extension study. Vermorken AJ; Zhu J; Van de Ven WJ; Andrès E Am J Hematol; 2012 Oct; 87(10):E80. PubMed ID: 22718517 [No Abstract] [Full Text] [Related]
39. Is multidrug resistance (P-glycoprotein) an intrinsic characteristic of plasma cells in patients with monoclonal gammopathy of undetermined significance, plasmacytoma, multiple myeloma and amyloidosis? Mongkonsritragoon W; Kimlinger T; Ahmann G; Greipp PR Leuk Lymphoma; 1998 May; 29(5-6):577-84. PubMed ID: 9643571 [TBL] [Abstract][Full Text] [Related]
40. Daratumumab monotherapy for patients with intermediate-risk or high-risk smoldering multiple myeloma: a randomized, open-label, multicenter, phase 2 study (CENTAURUS). Landgren CO; Chari A; Cohen YC; Spencer A; Voorhees P; Estell JA; Sandhu I; Jenner MW; Williams C; Cavo M; van de Donk NWCJ; Beksac M; Moreau P; Goldschmidt H; Kuppens S; Bandekar R; Clemens PL; Neff T; Heuck C; Qi M; Hofmeister CC Leukemia; 2020 Jul; 34(7):1840-1852. PubMed ID: 32024950 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]